{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T17:31:59Z","timestamp":1767202319029,"version":"build-2238731810"},"reference-count":20,"publisher":"National Institute for Health and Care Research","issue":"Suppl 1","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["06\/17-01"],"award-info":[{"award-number":["06\/17-01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:p>\n                    This paper presents a summary of the evidence review group (ERG) report into the clinical and cost-effectiveness of fludarabine phosphate or fludarabine plus cyclophosphamide for the first-line treatment of chronic lymphocytic leukaemia, based upon the evidence submission from Schering Health Care (SHC) to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process. The submission was of good quality with no major errors or omissions in the clinical evidence. Two published studies and seven abstracts were included in the company submission, which showed improvements in overall response and progression-free survival (PFS) and a higher complete response rate in the fludarabinecontaining arms; however, until the complete data are made available for evaluation these results must be interpreted with caution. The manufacturer\u2019s decision-analytic Markov model to estimate the cost-effectiveness of treatment with fludarabine monotherapy, fludarabine plus cyclophosphamide and chlorambucil was considered to be the most relevant source for informing this STA; it was appropriate for the decision problem and the data sources used to inform the model were appropriate from a UK NHS perspective. The incremental cost-effectiveness ratio of fludarabine plus cyclophosphamide compared with chlorambucil from the revised model presented in the manufacturer\u2019s addendum was \u00a33244 per additional quality-adjusted life-year. The results were robust to a range of subgroup and sensitivity analyses. Additional sensitivity and survival analyses were carried by the ERG to investigate possible bias in the results. This brought into question the validity of the assumptions underpinning the extrapolation of data over a lifetime time horizon and showed\n                    <jats:italic>t<\/jats:italic>\n                    hat the ICER estimates submitted by the manufacturer were not calculated correctly and uncertainty surrounding the decision problems was not expressed fully. Based on these analyses the ERG suggests that further evidence is needed to enable an accurate assessment to be made of the clinical and cost-effectiveness of fludarabine as first-line treatment for chronic lymphocytic leukaemia. The guidance issued by NICE in December 2006 as a result of the STA states that fludarabine monotherapy, within its licensed indication, is not recommended for the first-line treatment of chronic lymphocytic leukaemia; no recommendations have been made with respect to fludarabine plus cyclophosphamide combination therapy because the current marketing authorisation does not specifically provide a recommendation that fludarabine should be used concurrently with other drugs for the treatment of chronic lymphocytic leukaemia.\n                  <\/jats:p>","DOI":"10.3310\/hta13suppl1-06","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T13:12:28Z","timestamp":1613049148000},"page":"35-40","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia"],"prefix":"10.3310","volume":"13","author":[{"given":"S","family":"Walker","sequence":"first","affiliation":[{"name":"Centre for Health Economics, University of York and NHS Northern and Yorkshire Regional Drug and Therapeutics Centre, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Palmer","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York and NHS Northern and Yorkshire Regional Drug and Therapeutics Centre, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Erhorn","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York and NHS Northern and Yorkshire Regional Drug and Therapeutics Centre, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Brent","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York and NHS Northern and Yorkshire Regional Drug and Therapeutics Centre, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Dyker","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York and NHS Northern and Yorkshire Regional Drug and Therapeutics Centre, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Ferrie","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York and NHS Northern and Yorkshire Regional Drug and Therapeutics Centre, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Horsley","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York and NHS Northern and Yorkshire Regional Drug and Therapeutics Centre, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Macfarlane","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York and NHS Northern and Yorkshire Regional Drug and Therapeutics Centre, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"White","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York and NHS Northern and Yorkshire Regional Drug and Therapeutics Centre, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Thomas","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York and NHS Northern and Yorkshire Regional Drug and Therapeutics Centre, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6221","published-online":{"date-parts":[[2009,6]]},"reference":[{"key":"key20210211164952773_ref1-bib1","volume-title":"Guide to the single technology (STA) process","author":"National Institute for Health and Clinical Excellence","year":"2006"},{"key":"key20210211164952773_ref1-bib2","volume-title":"Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia","author":"Walker","year":"2006"},{"key":"key20210211164952773_ref1-bib3","volume-title":"CancerWEB online medical dictionary","author":"Centre for Cancer Education, University of Newcastle upon Tyne"},{"key":"key20210211164952773_ref1-bib4","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2141.2004.04898.x","article-title":"Guidelines on the diagnosis and management of chronic lymphocytic leukaemia","volume":"125","author":"Oscier","year":"2004","journal-title":"Br J Haematol"},{"key":"key20210211164952773_ref1-bib5","volume-title":"Oxford textbook of medicine","author":"Warell","year":"2003","edition":"4th"},{"key":"key20210211164952773_ref1-bib6","doi-asserted-by":"crossref","first-page":"i50","DOI":"10.1093\/annonc\/mdi806","article-title":"ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of chronic lymphocytic leukemia","volume":"16","author":"Hallek","year":"2005","journal-title":"Ann Oncol"},{"key":"key20210211164952773_ref1-bib7","unstructured":"Welsh Cancer Intelligence and Surveillance Unit. Cancer incidence 2003. Cardiff, 2005."},{"key":"key20210211164952773_ref1-bib8","unstructured":"Office for National Statistics. Cancer registrations in England 2003. London, 2005."},{"key":"key20210211164952773_ref1-bib9","unstructured":"Office for National Statistics. Components of population change (constituent countries of the United Kingdom). Population Trends 123, report D9255. 2005."},{"key":"key20210211164952773_ref1-bib10","doi-asserted-by":"crossref","first-page":"388","DOI":"10.4065\/79.3.388","article-title":"Current approach to diagnosis and management of chronic lymphocytic leukemia","volume":"79","author":"Shanafelt","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"key20210211164952773_ref1-bib11","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood"},{"key":"key20210211164952773_ref1-bib12","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N Engl J Med"},{"key":"key20210211164952773_ref1-bib13","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1182\/blood.V106.11.716.716","article-title":"Early results from LRF CLL4: a UK multicentre randomised trial. ASH Annual Meeting Abstracts","volume":"106","author":"Catovsky","year":"2005","journal-title":"Blood"},{"key":"key20210211164952773_ref1-bib14","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/blood.V106.11.717.717","article-title":"Comparison of the efficacy and toxicity of fludarabine (F) in firstline therapy of younger versus elderly patients (Pts) with advanced chronic lymphocytic leukemia (CLL): results of a meta-analysis of two phase III trials of the German CLL study group (GCLLSG). ASH Annual Meeting Abstracts","volume":"106","author":"Eichhorst","year":"2005","journal-title":"Blood"},{"key":"key20210211164952773_ref1-bib15","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1182\/blood.V104.11.3470.3470","article-title":"Cladribine (CdA) or fludarabine (F) or highdose intermittent chlorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukemia? First interim analysis of data from the international randomized phase III trial. ASH Annual Meeting Abstracts","volume":"104","author":"Karlsson","year":"2004","journal-title":"Blood"},{"key":"key20210211164952773_ref1-bib16","first-page":"93","article-title":"Multicentre prospective randomized trial of fludarabine versus chlorambucil and prednisone in previously untreated patients with active B-cell CLL: final report","volume":"42","author":"Spriano","year":"2000","journal-title":"Haematol Cell Ther"},{"key":"key20210211164952773_ref1-bib17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1182\/blood.V104.11.475.475","article-title":"Fludarabine and cyclophosphamide produces a higher complete response rate and more durable remissions than fludarabine in patients with previously untreated CLL: Intergroup Trial E2997. ASH Annual Meeting Abstracts","volume":"104","author":"Flinn","year":"2004","journal-title":"Blood"},{"key":"key20210211164952773_ref1-bib18","unstructured":"Schering Health Care Ltd, Fludarabine phosphate for the first-line treatment of chronic lymphcytic leukaemia 2006."},{"key":"key20210211164952773_ref1-bib19","volume-title":"Fludarabine in the treatment of chronic lymphocytic leukaemia","author":"Best","year":"1995"},{"key":"key20210211164952773_ref1-bib20","volume-title":"Fludarabine as first line therapy for chronic lymphocytic leukaemia","author":"Hancock","year":"2002"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2035561","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta13suppl1-06\/hta13suppl1-06.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2035561","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T11:37:40Z","timestamp":1692099460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta13suppl1-06"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":20,"aliases":["10.3310\/hta13suppl1\/06"],"journal-issue":{"issue":"Suppl 1","published-online":{"date-parts":[[2009,6]]}},"alternative-id":["10.3310\/hta13suppl1-06"],"URL":"https:\/\/doi.org\/10.3310\/hta13suppl1-06","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"6-2006","name":"date_of_ERG_submission","label":"Date of ERG submission","group":{"name":"article_history","label":"Article History"}},{"value":"7-2007","name":"editorial_review_begun","label":"Editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"12-2008","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}